FDA approves Evenity for osteoporosis

FDA approved Evenity (romosozumab-aqqg) from Amgen and UCB to treat osteoporosis in postmenopausal women at high risk of fracture. In January, an FDA advisory committee voted 18-1 in favor of the drug's approval (see "FDA Panel Backs Amgen's Evenity for Osteoporosis").